BNL-201
Pre-clinical- Indications
- Dandy Walker Syndrome
Company intelligence / Profile preview
Bionaut Labs has developed a novel platform using remote-controlled microscale robots (“Bionauts™”) to deliver drugs directly to targeted sites within the central nervous system. Their lead program for malignant glioma has received FDA Orphan Drug Designation; another program targeting Dandy-Walker Syndrome has received Humanitarian Use Device designation. The company’s approach enables localized treatment with improved efficacy and safety compared to traditional modalities. Clinical results are not yet published as programs remain preclinical or at early regulatory stages
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bionaut Labs.